Business Wire

When Regulation and AI Converge: SymphonyAI Joins the FCA Supercharged Sandbox to Pioneer Responsible Fintech Innovation

19.11.2025 08:00:00 CET | Business Wire | Press release

Share

SymphonyAI joins the FCA’s new Supercharged Sandbox to advance explainable, responsible AI innovation for UK financial services

SymphonyAI, a global leader in Vertical AI product platforms, has been selected to participate in the UK’s Financial Conduct Authority’s (FCA) Supercharged AI Sandbox, a new initiative enabling firms to safely develop and test advanced AI technologies using NVIDIA (NVDA) accelerated computing within a supervised regulatory environment.

SymphonyAI Financial Services was selected following a competitive application process that evaluated proposed use cases for innovation potential, technical feasibility, and regulatory impact.

Running from September 2025 to January 2026, the Sandbox offers a secure, structured environment for experimentation on next-generation AI use cases. SymphonyAI is developing an AI agent concept powered by small language models and reinforcement learning, designed to advance the intelligence and autonomy of financial services agents. If successful, the innovations developed in the Sandbox will be incorporated into SymphonyAI’s portfolio of intelligent financial services agents, further enhancing how financial institutions accelerate risk detection, improve compliance, and reduce investigation time.

“SymphonyAI has long been at the forefront of AI innovation in regulated industries,” said Jason Shane, Head of Product, Strategy and Innovation, Financial Services, SymphonyAI. “Our participation in the FCA’s sandbox programme underscores our leadership in Financial Services AI and our commitment to advancing responsible, explainable innovation. By incorporating these next-generation learnings directly into our AI agents, we’re giving customers the fastest, safest way to access the most advanced AI capabilities available, ensuring they stay ahead in risk management, compliance, and operational performance.”

Through its participation, SymphonyAI aims to:

  • Incubate a new AI innovation to benefit the financial crime risk and compliance community;
  • Accelerate the integration of next-generation AI agent capabilities, combining generative models, reinforcement learning, and domain-trained models, into our Sensa Risk Intelligence platform and broader Financial Services portfolio;
  • Collaborate with the FCA and industry peers to establish trusted and explainable AI innovation(s), that improve(s) the accuracy of outcomes and can securely scale in highly regulated financial services environments.

The 12-week program will culminate in showcase days on 28–29 January 2026 in London, where participants will present their innovations to regulators, financial institutions, academia, consultancies, and government representatives.

About the FCA’s Supercharged Sandbox

For more information about the FCA's Supercharged Sandbox, please visit: www.fca.org.uk/firms/innovation/ai-lab

SymphonyAI Participation Timeline

  • 30 September 2025: Virtual kickoff and bootcamp
  • 30 September 2025 – 9 January 2026: Tech sprint / development phase
  • 28–29 January 2026: Showcase days in London

About SymphonyAI

SymphonyAI delivers Vertical AI product platforms that help enterprises solve their most complex, high-value challenges — from stopping financial crime to improving store -performance and boosting manufacturing efficiency. Trusted by more than 2,000 enterprise customers worldwide, including 200 of the top financial institutions, the top 25 CPG companies, and many of the world’s largest grocers and industrial manufacturers, SymphonyAI provides domain-trained applications and pre-built agents that are ready to work on day one. Learn more at https://www.symphonyai.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251118157541/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye